Astrana Health (NASDAQ:ASTH) Rating Increased to Hold at Macquarie

Astrana Health (NASDAQ:ASTH - Get Free Report) was upgraded by Macquarie to a "hold" rating in a research note issued to investors on Monday,Zacks.com reports.

Other equities research analysts also recently issued reports about the company. BTIG Research lifted their price objective on Astrana Health from $60.00 to $70.00 and gave the company a "buy" rating in a report on Thursday, October 3rd. KeyCorp initiated coverage on Astrana Health in a research note on Friday, October 11th. They issued a "sector weight" rating on the stock. TD Cowen assumed coverage on Astrana Health in a research report on Monday, October 14th. They issued a "buy" rating and a $66.00 price target on the stock. Finally, Robert W. Baird lifted their price objective on Astrana Health from $67.00 to $86.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Astrana Health presently has an average rating of "Moderate Buy" and an average target price of $65.17.

Astrana Health Stock Performance

ASTH stock traded down $0.48 during midday trading on Monday, hitting $35.04. The stock had a trading volume of 339,796 shares, compared to its average volume of 213,782. Astrana Health has a 52 week low of $34.11 and a 52 week high of $63.20. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The stock has a 50-day simple moving average of $48.57 and a 200 day simple moving average of $48.08. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of 26.95, a P/E/G ratio of 1.80 and a beta of 1.13.

Astrana Health (NASDAQ:ASTH - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The company had revenue of $478.71 million during the quarter, compared to analysts' expectations of $462.01 million. During the same quarter in the prior year, the company posted $0.47 EPS. As a group, equities research analysts anticipate that Astrana Health will post 1.16 earnings per share for the current year.

Hedge Funds Weigh In On Astrana Health

A number of institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC bought a new position in shares of Astrana Health in the third quarter valued at about $34,000. Nisa Investment Advisors LLC acquired a new stake in Astrana Health in the 3rd quarter valued at about $35,000. KBC Group NV acquired a new stake in Astrana Health in the 3rd quarter valued at about $70,000. Quarry LP bought a new position in shares of Astrana Health in the third quarter worth about $77,000. Finally, Quest Partners LLC acquired a new position in shares of Astrana Health during the third quarter worth approximately $133,000. Institutional investors and hedge funds own 52.77% of the company's stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.